Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8187971 | 0.84 | OXER1 (0.43) | CCR2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL4467286 | 0.70 | DAO (0.47) | CCR2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL21803708 | 0.69 | DAO (0.43) | CCR2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL16835425 | 0.69 | OXER1 (0.46) | CCR2DAOALDH1A1 | |
| SCHEMBL29780995 | 0.68 | DAO (0.65) | CCR2DAOALDH1A1 | |
| SCHEMBL3638561 | 0.68 | DAO (0.65) | CCR2DAOALDH1A1 | |
| SCHEMBL17422801 | 0.68 | DAO (0.46) | CCR2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL5967722 | 0.68 | MCL1 (0.49) | DAOKDM4EALDH1A1HPGD | |
| SCHEMBL3843739 | 0.68 | DAO (0.46) | CCR2DAOKDM4EALDH1A1HPGD | |
| SCHEMBL30343692 | 0.68 | MCL1 (0.49) | DAOKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199985-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187471-B2 | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-25 | — | — | US | disclosed |
| WO-2011103430-A1 | PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | CCR2 3316/4885BCL2 2311/4885BCL2L1 3178/4885 |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | CCR2 1029/4885BCL2 2578/4885BCL2L1 3673/4885 |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2C, ADRA2B | CCR2 589/4885BCL2 742/4885BCL2L1 2272/4885 |
| US-20160030446-A1 | PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | CCR2 3316/4885BCL2 2311/4885BCL2L1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.